Eli Lilly and Company (LLY)
| Market Cap | 657.66B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 47.90 |
| Forward PE | 26.42 |
| Dividend | $6.00 (0.82%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 2,549,410 |
| Open | 732.32 |
| Previous Close | 731.96 |
| Day's Range | 728.50 - 737.42 |
| 52-Week Range | 623.78 - 969.65 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 978.56 (+33.58%) |
| Earnings Date | Aug 7, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $978.56, which is an increase of 33.58% from the latest price.
News
Eli Lilly Is Proof That Wall Street Stars Don't Have To Be Tech Titans
Although the stock has experienced its fair share of turbulence in 2025, Eli Lilly LLY is rapidly emerging as a key consideration for investors seeking to hedge their portfolios away from tech and AI ...
Eli Lilly joins forces with China tech giant to expand obesity drug market
Eli Lilly has partnered with a leading Chinese tech company, JD Health to fast-track its presence in China's rapidly expanding obesity drug market, boosting the company's global growth in the weight-l...
Healthcare Stocks Are ‘Priced at Panic Levels.' It's Time to Buy.
They're bargains right now, according to two key measures. Expert Jim Paulsen won't venture a guess when the prices will recover.
Stock Of The Day: Another Breakout For Eli Lilly?
Trading is quiet in Eli Lilly and Co LLY on Thursday. The stock has stalled out at a resistance level.
Eli Lilly: In The Eye Of The Drug Pricing Storm - Expect Volatility, And Buy
Eli Lilly's explosive growth is driven by GLP-1 drugs Mounjaro and Zepbound, with tirzepatide becoming a historic best-seller in obesity and diabetes. President Trump's aggressive drug pricing reforms...
Eli Lilly: Orals Unlock The Next Wave Of Obesity Drug Adoption
Eli Lilly and Company's orforglipron shows strong efficacy and manufacturing advantages over Novo Nordisk's oral semaglutide, supporting future growth in the obesity and diabetes market. Orforglipron'...
Eli Lilly: Why I'm Pairing It With My Novo Position
Eli Lilly and Company is a leader in cardiometabolic medicine, with strong R&D, innovative obesity and diabetes drugs, and expanding oncology and neuroscience portfolios. Recent clinical wins, especia...
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the treatment set to come into effect starting next month.
The bear case on Eli Lilly has played out, says only firm to have called it a sell
The bear case for Eli Lilly has now played out following the reaction to the drugmaker's oral obesity drug trial, an analyst said Wednesday in upgrading the stock.
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...
Citi's Geoff Meacham on Eli Lilly's stock climbing as weight loss pill clears latest trial
Geoff Meacham, Citi Research Managing Director, joins 'Fast Money' to talk competition in the weight loss drug space as Eli Lilly's weight loss pill clears its latest trial.
S&P 500 Gains and Losses Today: Eli Lilly Stock Soars as Weight-Loss Pill Shows Promise; Beverage Makers Face Pressure
Major U.S. equities indexes ticked higher as investors looked past concerns about President Donald Trump's effort to remove Federal Reserve Governor Lisa Cook and ahead to Wednesday's Nvidia earnings ...
Healthy Returns: Eli Lilly's chief scientific officer breaks down the latest obesity pill data
Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving quickly on a strategic turnaround.
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly and Co. LLY stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.
Top Stock Movers Now: Eli Lilly, EchoStar, Constellation Brands, and More
U.S. equities were little changed at midday on limited market-driving corporate earnings news and economic data. The Dow Jones Industrial Average, S&P 500, and Nasdaq all moved by small amounts.
Eli Lilly's Obesity Pill Moves Closer to Approval
Eli Lilly & Co.'s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval. Damian Garde has more on "Bloomber...
Guggenheim Partner's Seamus Fernandez: Oral weight loss pill 'meaningful step up' for Eli Lilly
Seamus Fernandez, Guggenheim Partners biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest data on Eli Lilly's obesity pill.
LLY Weight Loss Drug Momentum, AT&T's (T) $23B EchoStar Licenses, ULTA Price Target Hikes
AT&T (T) secured a deal worth $23 billion with EchoStar (SATS) to buy spectrum licenses from the company. Eli Lilly (LLY) tacked on billions of dollars in market share after its experimental weight lo...
Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval
Eli Lilly (LLY) shares gained more than 4% soon after the opening bell Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.
Cramer's Stop Trading: Eli Lilly
Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly.
Lilly obesity-pill trial results find a warmer reception on Wall Street this time around
Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.
Eli Lilly's weight loss pill will likely be the market-leading product, says BofA's Tim Anderson
Tim Anderson, BofA Securities senior pharma analyst, joins 'Squawk Box' to discuss news of Eli Lilly's weight loss pill orforglipron clearing its latest trial, what it means for the drug going forward...
Eli Lilly stock jumps in pre-market trading: what's driving the surge?
Eli Lilly & Co's experimental obesity pill orforglipron helped patients lose 9.6% of their body weight in a late-stage trial, moving the drug a step closer to potential approval.
Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals
Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.
Lilly pill cuts body weight by 10.5% in patients with type 2 diabetes
Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in...